Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

MK-5172/MK-8742 is an all-oral combination regimen consisting of MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

Published
23 October 2013
From
Merck press release
Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection

The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks

Published
22 October 2013
By
Liz Highleyman
Simeprevir with interferon effective for HIV/HCV co-infected people with genotype 1 hepatitis C

Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported

Published
21 October 2013
By
Liz Highleyman
New drugs will bring revolution in hepatitis C treatment

The advent of direct-acting antiviral agents can rightly be described as a revolution in treatment for chronic hepatitis C, but potential challenges remain – including drug interactions

Published
18 October 2013
By
Liz Highleyman
Interferon-free therapy alters lipid metabolism, glucose homeostasis in chronic HCV patients

Patients with chronic hepatitis C treated with an interferon-free regimen consisting of sofosbuvir and ribavirin experienced changes in LDL, triglycerides, hemoglobin A1C and metabolic and hepatic lipid gene expression in a study presented at ID Week 2013.

Published
14 October 2013
From
Healio Hepatology
Enter the Nonspecialist: Will Evolving Hepatitis C Therapies Reduce the Need for Specialized Care?

After the advent of the single-tablet regimen, what will be the place of the specialist? We will take a step back as nonspecialists gradually assume a larger role managing patients with few comorbidities and little or no liver disease. For myself, I expect the face of my practice will change; 5 years from now, it will probably be composed entirely of a subset of very complicated patients who may need the benefits of interferon and the experience using it that a specialist provides.

Published
14 October 2013
From
Clinical Care Options (requires registration)
Predicting response to acute hepatitis C treatment in HIV/HCV co-infected people

HIV/HCV co-infected people with higher HCV viral load, lower CD4 cell counts, older age and unfavourable IL28B status may not respond as well to interferon-based treatment for

Published
14 October 2013
By
Liz Highleyman
Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen

A short 12- or 16-week triple regimen of daclatasvir plus pegylated interferon/ribavirin cured more people than a 24-week course of pegylated interferon/ribavirin alone, whilst an interferon-free regimen containing

Published
10 October 2013
By
Liz Highleyman
Idenix Shares Fall as J&J Buys Rival Hepatitis C Therapy

J&J, the world’s largest seller of health-care products, bought rights to a compound from London-based GlaxoSmithKline Plc in a class of drugs called non-structural 5A protein inhibitors. That suggests J&J may be close to ending a partnership with Idenix on its hepatitis C therapies including the NS5a drug samatasvir, Brian Abrahams, an analyst with Wells Fargo & Co., said today in a note to clients.

Published
08 October 2013
From
Bloomberg
Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

This ongoing study evaluates a new 12-week interferon-free regimen of Boehringer Ingelheim’s protease inhibitor, faldaprevir*, and non-nucleoside NS5B polymerase inhibitor, deleobuvir*, in combination with Presidio’s pan-genotypic HCV NS5A inhibitor, PPI-668*, with and without ribavirin

Published
08 October 2013
From
Boehringer-Ingelheim press release

Filter by country